Video

Edward Fox, MD, Discusses the Extension Study of Alemtuzumab for MS

Neurology Reviews. 2013 April;21(4):602

 

Online-Only Materials

AttachmentSize
File 021040602.mp463.15 MB

Recommended Reading

Bill seeks to keep biologic copays down
MDedge Neurology
Reducing glatiramer acetate dosing frequency seems reasonable
MDedge Neurology
Second-line indication for daclizumab seems likely
MDedge Neurology
'Liberation therapy' may make MS worse
MDedge Neurology
FDA approves Tecfidera for multiple sclerosis
MDedge Neurology
Teriflunomide Does Not Interfere With Seasonal Flu Vaccination in Patients With MS
MDedge Neurology
New and Noteworthy Information—February
MDedge Neurology
Commentary—Oral MS Therapies Show Promise and Raise Questions
MDedge Neurology
New and Noteworthy Information—March
MDedge Neurology
FROM AAN'S 2013 ANNUAL MEETING—Early Detection of PML May Improve Survival and Reduce Disability in MS
MDedge Neurology